Category
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Today's News
More News
Trial results show PARP inhibitor benefit in 'BRCA-like' breast cancer

Trial results show PARP inhibitor benefit in 'BRCA-like' breast cancer

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainResults from the SWOG S1416 clinical trial show that adding veliparib to chemotherapy can significantly extend progression-free surviva

Trial results show PARP inhibitor benefit in 'BRCA-like' breast cancer

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainResults from the SWOG S1416 clinical trial show that adding veliparib to chemotherapy can significantly extend progression-free surviva
Results of trial will help guide treatment of malignant bowel obstruction in patients with advanced cancer

Results of trial will help guide treatment of malignant bowel obstruction in patients with advanced cancer

by SWOG Cancer Research NetworkCredit: CC0 Public DomainFindings from the first-ever prospective trial including a randomized pathway comparing surgery to non-surgical treatment of malignant bowel obs

Results of trial will help guide treatment of malignant bowel obstruction in patients with advanced cancer

by SWOG Cancer Research NetworkCredit: CC0 Public DomainFindings from the first-ever prospective trial including a randomized pathway comparing surgery to non-surgical treatment of malignant bowel obs
Trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutations

Trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutations

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity,

Trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutations

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity,
Trial finds adding immune modulator to targeted therapy does not improve survival in difficult-to-treat thyroid cancer

Trial finds adding immune modulator to targeted therapy does not improve survival in difficult-to-treat thyroid cancer

byUniversity of Chicago Medical CenterCredit: Pixabay/CC0 Public DomainResults of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show

Trial finds adding immune modulator to targeted therapy does not improve survival in difficult-to-treat thyroid cancer

byUniversity of Chicago Medical CenterCredit: Pixabay/CC0 Public DomainResults of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show
Chemotherapy before surgery cuts risk of colon cancer returning, trial finds

Chemotherapy before surgery cuts risk of colon cancer returning, trial finds

byCancer Research UKCredit: CC0 Public DomainGiving colon cancer patients chemotherapy before surgery cuts their risk of the disease coming back, according to the results of a Cancer Research UK

Chemotherapy before surgery cuts risk of colon cancer returning, trial finds

byCancer Research UKCredit: CC0 Public DomainGiving colon cancer patients chemotherapy before surgery cuts their risk of the disease coming back, according to the results of a Cancer Research UK
Inhibition of prmt5 by repurposing market drugs: A fresh therapeutic pathway for cancer treatment

Inhibition of prmt5 by repurposing market drugs: A fresh therapeutic pathway for cancer treatment

by TranSpreadDevelopment of AlphaLISA HTS screen to identify specific PRMT5 inhibitors. (A) Principle of AlphaLISA technique adapted to HTS. Biotinylated histone H4 (a well-known PRMT5 substrate) was

Inhibition of prmt5 by repurposing market drugs: A fresh therapeutic pathway for cancer treatment

by TranSpreadDevelopment of AlphaLISA HTS screen to identify specific PRMT5 inhibitors. (A) Principle of AlphaLISA technique adapted to HTS. Biotinylated histone H4 (a well-known PRMT5 substrate) was
World-first use of base-edited CAR T cells to treat resistant leukemia

World-first use of base-edited CAR T cells to treat resistant leukemia

byUniversity College LondonCredit: Unsplash/CC0 Public DomainA patient with relapsed T cell leukaemia has been given base-edited T-cells in a world-first use of a base-edited cell therapy, in a

World-first use of base-edited CAR T cells to treat resistant leukemia

byUniversity College LondonCredit: Unsplash/CC0 Public DomainA patient with relapsed T cell leukaemia has been given base-edited T-cells in a world-first use of a base-edited cell therapy, in a
World-first clinical trial with 'man's best friend' could unlock treatment breakthrough for kids with cancer

World-first clinical trial with 'man's best friend' could unlock treatment breakthrough for kids with cancer

by Telethon Kids InstituteThree-year-old Bull Terrier, Maggie, is about to undergo surgery using the immunotherapy gel to treat her sarcoma. It is hoped the world-first clinical trial in dogs will be

World-first clinical trial with 'man's best friend' could unlock treatment breakthrough for kids with cancer

by Telethon Kids InstituteThree-year-old Bull Terrier, Maggie, is about to undergo surgery using the immunotherapy gel to treat her sarcoma. It is hoped the world-first clinical trial in dogs will be
World-first guidelines created to help prevent heart complications in children during cancer treatment

World-first guidelines created to help prevent heart complications in children during cancer treatment

byMurdoch Children's Research InstituteThe world's first international clinical guidelines to help prevent and treat heart complications in children undergoing cancer treatment have been

World-first guidelines created to help prevent heart complications in children during cancer treatment

byMurdoch Children's Research InstituteThe world's first international clinical guidelines to help prevent and treat heart complications in children undergoing cancer treatment have been
Normalizing tumor blood vessels may improve immunotherapy against brain cancer

Normalizing tumor blood vessels may improve immunotherapy against brain cancer

by Noah Brown,Massachusetts General HospitalAnti-VEGF treatment improves the efficacy of EGFRvIII-CAR-T cells in murine GBM tumor models. (A) Schematic representation of experimental setup to ev

Normalizing tumor blood vessels may improve immunotherapy against brain cancer

by Noah Brown,Massachusetts General HospitalAnti-VEGF treatment improves the efficacy of EGFRvIII-CAR-T cells in murine GBM tumor models. (A) Schematic representation of experimental setup to ev
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...